NasdaqCM:CORTPharmaceuticals
Assessing Corcept Therapeutics (CORT) Valuation After Bullish Analyst Views on Korlym and Relacorilant’s PDUFA Milestone
Corcept Therapeutics (CORT) is back in focus after fresh analyst commentary spotlighted growing Korlym sales and rising expectations for relacorilant ahead of its key PDUFA decision for Cushing’s syndrome.
See our latest analysis for Corcept Therapeutics.
The stock has been repricing that optimism fast, with a roughly 16 percent 1 month share price return, a 26 percent 3 month share price return, and a powerful 3 year total shareholder return of about 338 percent, pointing to clear, building...